Chapter 29: Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth

Chronic lymphocytic leukemia: Monoclonal antibodies will drive steady growth Chronic lymphocytic leukemia (CLL), which is considered incurable, is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival, particularly for patients with advanced disease. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market. In this chapter, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We focus on the US market for this chapter because the United States accounts for approximately 80% of CLL market sales, largely because of the higher cost of CLL agents in this market compared to other markets. We ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book